|
시장보고서
상품코드
2091475
맨틀세포 림프종 치료제 시장 규모, 점유율, 성장 분석 : 종류별, 작용기전별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Mantle Cell Lymphoma Therapeutics Market Size, Share, and Growth Analysis, By Type (Combination Therapy, Monotherapy), By Mechanism of Action, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 맨틀세포 림프종 치료제 시장 규모는 2024년에 24억 1,000만 달러로 평가되었으며, 2025년 26억 1,000만 달러에서 2033년까지 48억 9,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 8.2%로 성장할 것으로 전망됩니다.
맨틀세포 림프종 치료제 시장은 이 B세포 암의 발병률 증가와 더불어, 보다 효과적인 치료법에 대한 미충족 의료 수요가 뒷받침되면서 급속히 확대되고 있습니다. 수년까지 치료 양상은 기존의 화학면역요법에서 표적 지향성 저분자 약물, 항체약물접합체(ADC), 세포 치료법 등 첨단 치료 옵션을 포함하는 형태로 변화해 왔습니다. 생존율이 여전히 제한적이기 때문에 더 효과적인 대체 요법에 대한 수요가 증가하고 있으며, 이러한 변화는 매우 중요합니다. 이부르티닙의 도입은 치료 성과에 있어 전환점이 되었으며, 그 후 혁신적인 치료법들이 잇달아 승인되면서 시장은 다양화되었습니다. 이러한 표적 치료법의 적용 확대와 비용 대비 효과에 대한 관심 증가는, 특히 유럽과 아시아의 고령화 추세에 따라 암 치료 분야에서 새로운 해결책이 요구되는 가운데, 시장 침투를 촉진할 것으로 전망됩니다.
세계 맨틀세포 림프종 치료제 시장의 성장요인
분자 기술과 영상 진단 기술의 발전으로 맨틀세포 림프종의 조기 발견률이 크게 향상되어, 의료진은 질병의 진행 단계가 낮은 시점에서 표적 치료를 시작할 수 있게 되었습니다. 이러한 정밀한 진단을 통해 치료 저항성이 최소화되고 환자의 예후가 개선됨에 따라, 임상의들은 혁신적인 치료법을 우선적으로 선택하고 있습니다. 그 결과, 전문 의약품에 대한 수요가 증가하고 있으며, 이는 조사에 대한 투자를 촉진하는 동시에 전 세계 의료 시스템 내에서 시장의 입지를 확대하고 있습니다. 또한, 진단 정확도에 대한 신뢰도가 높아짐에 따라 보험 적용 범위가 확대되어, 환자들이 새롭고 효과적인 치료 옵션을 더 쉽게 이용할 수 있게 되었습니다.
세계 맨틀세포 림프종 치료제 시장의 제약요인
맨틀세포 림프종 치료제, 특히 혁신적인 표적 치료나 병용요법에 수반되는 고액의 비용은 의료 예산과 환자 모두에게 막대한 경제적 부담을 안겨주고 있습니다. 보험사는 종종 엄격한 환급 기준을 적용하여, 특정 환자 집단이 가장 효과적인 약물을 이용할 기회를 제한하고 있습니다. 이러한 비용에 대한 민감성은 예산을 중시하는 시장에서 신속한 도입을 저해할 가능성이 있으며, 의료 서비스 제공자들이 가격은 더 저렴하지만 효과는 떨어지는 대체 요법을 선택할 수밖에 없게 만들어, 재정 자원이 제한된 지역에서는 시장 성장을 저해할 우려가 있습니다. 게다가, 빈번한 경과 관찰을 위해 병원을 방문해야 하기 때문에 전체 치료비가 크게 증가합니다.
세계 맨틀세포 림프종 치료제 시장의 동향
세계 맨틀세포 림프종 치료제 시장에서는 차세대 CAR-T 세포 및 이중특이성항체와 같은 혁신적인 치료법의 도입을 배경으로, 정밀 면역요법으로의 큰 전환이 나타나고 있습니다. 이러한 표적 치료법은 종양 특이적 항원에 초점을 맞추고 있어, 건강한 조직에 대한 손상을 최소화하면서 치료 효과를 높이는 데 기여하고 있습니다. 임상 협력이 강화되고, 환자 중심의 임상시험을 통해 확고한 실세계 데이터가 확보됨에 따라, 의료 제도는 전문 수액 치료 센터로의 자원 재분배 및 연수 프로그램 확충과 같은 조치를 추진했습니다. 이러한 전략적 투자는 의사들의 신뢰를 높이고, 대학병원과 지역 암 진료 현장 모두에서 광범위한 도입을 촉진하며, 치료 환경에서 지속가능한 추진력을 창출하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 맨틀세포 림프종 치료제 시장 규모 : 유형별
세계의 맨틀세포 림프종 치료제 시장 규모 : 작용기전별
세계의 맨틀세포 림프종 치료제 시장 규모 : 투여 경로별
세계의 맨틀세포 림프종 치료제 시장 규모 : 최종사용자별
세계의 맨틀세포 림프종 치료제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.23Global Mantle Cell Lymphoma Therapeutics Market size was valued at USD 2.41 Billion in 2024 and is poised to grow from USD 2.61 Billion in 2025 to USD 4.89 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).
The mantle cell lymphoma therapeutics market is expanding significantly, driven by the rising incidence of this B-cell cancer alongside an unmet medical need for more effective treatments. Over the years, the landscape has evolved from traditional chemo-immunotherapy to include advanced options such as targeted small molecules, antibody-drug conjugates, and cellular therapies. This shift is critical as survival rates remain limited, prompting demand for better alternatives. The introduction of ibrutinib marked a turning point in treatment outcomes, while subsequent approvals of innovative therapies have diversified the market. The growing adoption of these targeted therapies and the increasing focus on cost-effectiveness will likely enhance market penetration, particularly as aging populations in Europe and Asia demand novel solutions in oncology.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mantle Cell Lymphoma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Mantle Cell Lymphoma Therapeutics Market Segments Analysis
Global mantle cell lymphoma therapeutics market is segmented by type, mechanism of action, route of administration, end user and region. Based on type, the market is segmented into combination therapy and monotherapy. Based on mechanism of action, the market is segmented into Bruton tyrosine kinase (BTK) inhibitors, alkylating agents, DNA synthesis inhibitors, microtubule inhibitors, monoclonal antibodies and others. Based on route of administration, the market is segmented into oral and parenteral. Based on end user, the market is segmented into hospitals, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Mantle Cell Lymphoma Therapeutics Market
Advancements in molecular and imaging technologies have significantly enhanced the early detection of mantle cell lymphoma, enabling healthcare professionals to initiate targeted therapies during less advanced stages of the disease. This precision in diagnosing the condition minimizes treatment resistance, leading to improved patient outcomes, which prompts clinicians to favor innovative therapeutics. Consequently, there is a growing demand for specialized pharmaceutical products, driving investment in research and expanding market presence within healthcare systems worldwide. Additionally, heightened confidence in diagnostic precision encourages broader insurance coverage, further facilitating patient access to new and effective treatment options.
Restraints in the Global Mantle Cell Lymphoma Therapeutics Market
The elevated expenses associated with mantle cell lymphoma therapeutics, particularly for innovative targeted treatments and combination therapies, create significant financial burdens on both healthcare budgets and patients. Insurers frequently impose stringent criteria for reimbursement, limiting access to the most effective medications for specific patient groups. This cost sensitivity can hinder rapid adoption in markets that are budget-conscious, prompting healthcare providers to opt for more affordable, yet less effective alternatives, which can stifle market growth in regions with constrained financial resources. Furthermore, the requirement for frequent follow-up appointments substantially adds to the overall treatment costs.
Market Trends of the Global Mantle Cell Lymphoma Therapeutics Market
The Global Mantle Cell Lymphoma Therapeutics market is witnessing a significant shift towards precision immunotherapy, driven by the introduction of innovative treatments such as next-generation CAR-T cells and bispecific antibodies. These targeted therapies focus on tumor-specific antigens, leading to improved efficacy while minimizing damage to healthy tissues. As clinical collaborations deepened and patient-centric trials generated robust real-world evidence, healthcare systems adapted by reallocating resources to specialized infusion centers and enhancing training programs. This strategic investment fosters physician confidence and stimulates broad adoption across both academic and community oncology settings, creating a sustainable momentum in the therapeutic landscape.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Mantle Cell Lymphoma Therapeutics Market Size by Type & CAGR (2026-2033)
- Market Overview
- Combination Therapy
- Chemotherapy Combinations
- Targeted Therapy Combinations
- Immunotherapy Combinations
- Monotherapy
- Single-Agent Chemotherapy
- Targeted Therapy Monotherapy
- Immunotherapy Monotherapy
Global Mantle Cell Lymphoma Therapeutics Market Size by Mechanism of Action & CAGR (2026-2033)
- Market Overview
- Bruton Tyrosine Kinase (BTK) Inhibitors
- Alkylating Agents
- DNA Synthesis Inhibitors
- Microtubule Inhibitors
- Monoclonal Antibodies
- Others
Global Mantle Cell Lymphoma Therapeutics Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Parenteral
Global Mantle Cell Lymphoma Therapeutics Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Research Institutes
- Others
Global Mantle Cell Lymphoma Therapeutics Market Size & CAGR (2026-2033)
- North America (Type, Mechanism of Action, Route of Administration, End User)
- US
- Canada
- Europe (Type, Mechanism of Action, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Mechanism of Action, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Mechanism of Action, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Mechanism of Action, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BeiGene Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (Janssen)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celgene Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharmacyclics LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sunesis Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kymera Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fate Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Actinium Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nurix Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- VelosBio Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Morphosys AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Innate Pharma SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
